After a 5th Circuit ruling curtailed telehealth and mail distribution, drugmakers filed emergency appeals seeking to restore broader access. Those appeals prompted the Supreme Court to temporarily preserve mail delivery of mifepristone while the case proceeds; drugmakers continue to press for relief as litigation moves forward.
Click a connection line between nodes to view confidence and evidence.